Cargando…

Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis

OBJECTIVE: To evaluate whether cotrimoxazole prophylaxis prevents common skin conditions in HIV-infected children. DESIGN: Open-label randomized controlled trial of continuing versus stopping daily cotrimoxazole (post-hoc analysis). SETTING: Three sites in Uganda and one in Zimbabwe. PARTICIPANTS: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Prendergast, Andrew J., Bwakura-Dangarembizi, Mutsa, Mugyenyi, Peter, Lutaakome, Joseph, Kekitiinwa, Adeodata, Thomason, Margaret J., Gibb, Diana M., Walker, A. Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976221/
https://www.ncbi.nlm.nih.gov/pubmed/27662556
http://dx.doi.org/10.1097/QAD.0000000000001264
_version_ 1783327139390554112
author Prendergast, Andrew J.
Bwakura-Dangarembizi, Mutsa
Mugyenyi, Peter
Lutaakome, Joseph
Kekitiinwa, Adeodata
Thomason, Margaret J.
Gibb, Diana M.
Walker, A. Sarah
author_facet Prendergast, Andrew J.
Bwakura-Dangarembizi, Mutsa
Mugyenyi, Peter
Lutaakome, Joseph
Kekitiinwa, Adeodata
Thomason, Margaret J.
Gibb, Diana M.
Walker, A. Sarah
author_sort Prendergast, Andrew J.
collection PubMed
description OBJECTIVE: To evaluate whether cotrimoxazole prophylaxis prevents common skin conditions in HIV-infected children. DESIGN: Open-label randomized controlled trial of continuing versus stopping daily cotrimoxazole (post-hoc analysis). SETTING: Three sites in Uganda and one in Zimbabwe. PARTICIPANTS: A total of 758 children aged more than 3 years receiving antiretroviral therapy (ART) for more than 96 weeks in the ARROW trial were randomized to stop (n = 382) or continue (n = 376) cotrimoxazole after median (interquartile range) 2.1(1.8, 2.2) years on ART. INTERVENTION: Continuing versus stopping daily cotrimoxazole. MAIN OUTCOME MEASURES: Nurses screened for signs/symptoms at 6-week visits. This was a secondary analysis of ARROW trial data, with skin complaints categorized blind to randomization as bacterial, fungal, or viral infections; dermatitis; pruritic papular eruptions (PPEs); or others (blisters, desquamation, ulcers, and urticaria). Proportions ever reporting each skin complaint were compared across randomized groups using logistic regression. RESULTS: At randomization, median (interquartile range) age was 7 (4, 11) years and CD4(+) was 33% (26, 39); 73% had WHO stage 3/4 disease. Fewer children continuing cotrimoxazole reported bacterial skin infections over median 2 years follow-up (15 versus 33%, respectively; P < 0.001), with similar trends for PPE (P = 0.06) and other skin complaints (P = 0.11), but not for fungal (P = 0.45) or viral (P = 0.23) infections or dermatitis (P = 1.0). Bacterial skin infections were also reported at significantly fewer clinic visits (1.2 versus 3.0%, P < 0.001). Independent of cotrimoxazole, bacterial skin infections were more common in children aged 6–8 years, with current CD4(+) cell count less than 500 cells/μl, WHO stage 3/4, less time on ART, and lower socio-economic status. CONCLUSION: Long-term cotrimoxazole prophylaxis reduces common skin complaints, highlighting an additional benefit for long-term prophylaxis in sub-Saharan Africa.
format Online
Article
Text
id pubmed-5976221
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-59762212018-06-15 Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis Prendergast, Andrew J. Bwakura-Dangarembizi, Mutsa Mugyenyi, Peter Lutaakome, Joseph Kekitiinwa, Adeodata Thomason, Margaret J. Gibb, Diana M. Walker, A. Sarah AIDS Clinical Science: Concise Communications OBJECTIVE: To evaluate whether cotrimoxazole prophylaxis prevents common skin conditions in HIV-infected children. DESIGN: Open-label randomized controlled trial of continuing versus stopping daily cotrimoxazole (post-hoc analysis). SETTING: Three sites in Uganda and one in Zimbabwe. PARTICIPANTS: A total of 758 children aged more than 3 years receiving antiretroviral therapy (ART) for more than 96 weeks in the ARROW trial were randomized to stop (n = 382) or continue (n = 376) cotrimoxazole after median (interquartile range) 2.1(1.8, 2.2) years on ART. INTERVENTION: Continuing versus stopping daily cotrimoxazole. MAIN OUTCOME MEASURES: Nurses screened for signs/symptoms at 6-week visits. This was a secondary analysis of ARROW trial data, with skin complaints categorized blind to randomization as bacterial, fungal, or viral infections; dermatitis; pruritic papular eruptions (PPEs); or others (blisters, desquamation, ulcers, and urticaria). Proportions ever reporting each skin complaint were compared across randomized groups using logistic regression. RESULTS: At randomization, median (interquartile range) age was 7 (4, 11) years and CD4(+) was 33% (26, 39); 73% had WHO stage 3/4 disease. Fewer children continuing cotrimoxazole reported bacterial skin infections over median 2 years follow-up (15 versus 33%, respectively; P < 0.001), with similar trends for PPE (P = 0.06) and other skin complaints (P = 0.11), but not for fungal (P = 0.45) or viral (P = 0.23) infections or dermatitis (P = 1.0). Bacterial skin infections were also reported at significantly fewer clinic visits (1.2 versus 3.0%, P < 0.001). Independent of cotrimoxazole, bacterial skin infections were more common in children aged 6–8 years, with current CD4(+) cell count less than 500 cells/μl, WHO stage 3/4, less time on ART, and lower socio-economic status. CONCLUSION: Long-term cotrimoxazole prophylaxis reduces common skin complaints, highlighting an additional benefit for long-term prophylaxis in sub-Saharan Africa. Lippincott Williams & Wilkins 2016-11-28 2016-11-08 /pmc/articles/PMC5976221/ /pubmed/27662556 http://dx.doi.org/10.1097/QAD.0000000000001264 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0, where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Clinical Science: Concise Communications
Prendergast, Andrew J.
Bwakura-Dangarembizi, Mutsa
Mugyenyi, Peter
Lutaakome, Joseph
Kekitiinwa, Adeodata
Thomason, Margaret J.
Gibb, Diana M.
Walker, A. Sarah
Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
title Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
title_full Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
title_fullStr Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
title_full_unstemmed Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
title_short Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis
title_sort reduced bacterial skin infections in hiv-infected african children randomized to long-term cotrimoxazole prophylaxis
topic Clinical Science: Concise Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5976221/
https://www.ncbi.nlm.nih.gov/pubmed/27662556
http://dx.doi.org/10.1097/QAD.0000000000001264
work_keys_str_mv AT prendergastandrewj reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT bwakuradangarembizimutsa reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT mugyenyipeter reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT lutaakomejoseph reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT kekitiinwaadeodata reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT thomasonmargaretj reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT gibbdianam reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis
AT walkerasarah reducedbacterialskininfectionsinhivinfectedafricanchildrenrandomizedtolongtermcotrimoxazoleprophylaxis